Figure 3From: Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsInfluence of treatment duration and chemotherapy applied in the last 3Â months on trastuzumab-mediated ADCC/ADCP. The extent of ADCC/ADCP was determined by flow cytometry and is shown in % of total tumor cell counts. An E/T ratio of 25:1 was used. White boxplots represent baseline ADCC/ADCP without trastuzumab (-) and light grey stimulation with trastuzumab (+). Applied chemotherapy (CTx) is indicated on the bottom. A, C) ADCC. B, D) ADCP.Back to article page